NanoVibronix Inc. (NAOV)
Company Description
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy.
Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing.
The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally.
NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.

Country | United States |
IPO Date | May 28, 2015 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 31 |
CEO | Brian M. Murphy |
Contact Details
Address: 525 Executive Boulevard Elmsford, New York United States | |
Website | https://www.nanovibronix.com |
Stock Details
Ticker Symbol | NAOV |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001326706 |
CUSIP Number | 63008J108 |
ISIN Number | US63008J6038 |
Employer ID | 00-0000000 |
SIC Code | 3842 |
Key Executives
Name | Position |
---|---|
Brian M. Murphy | Chief Executive Officer & Director |
Dr. Harold Jacob M.D. | Chief Medical Officer |
Lindsey Harrison | Vice President of Sales |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 20, 2025 | 10-Q | Quarterly Report |
May 19, 2025 | SCHEDULE 13G | Filing |
May 16, 2025 | 8-K | Current Report |
May 16, 2025 | 424B4 | Filing |
May 15, 2025 | NT 10-Q | Filing |
May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
May 14, 2025 | S-1/A | [Amend] Filing |
May 12, 2025 | S-1/A | [Amend] Filing |
Apr 29, 2025 | S-1/A | [Amend] Filing |
Apr 22, 2025 | S-1/A | [Amend] Filing |